Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells

Molecular Pharmaceutics

Volumn 11, Issue 6, 2014, Pages 1906-1918

  Satsangi, Arpan ^a,b   Roy, Sudipa S ^c   Satsangi, Rajiv K ^d   Vadlamudi, Ratna K ^c   Ong, Joo L ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b The University of Texas at San Antonio   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d Rann Research Corporation   (United States)

Author keywords

active targeting; biocleavable linker; breast cancer; cathepsin B; drug delivery; paclitaxel dendrimer conjugate

Indexed keywords

CATHEPSIN B; PACLITAXEL; PACLITAXEL PRODRUG CONJUGATE; POLYAMIDOAMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DENDRIMER; GLY-PHE-LEU-GLY; OLIGOPEPTIDE; PAMAM STARBURST; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CARCINOGENICITY; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CONFORMATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MELTING POINT; MITOSIS INHIBITION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; GENETICS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CATHEPSIN B; CELL LINE, TUMOR; CELL SURVIVAL; DENDRIMERS; FEMALE; HUMANS; MICE; OLIGOPEPTIDES; PACLITAXEL; PRODRUGS; UP-REGULATION;

EID: 84901766632     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500128k     Document Type: Article

References (65)

1. American Cancer Society. Cancer Facts and Figures 2013. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/ index (accessed May 20, 2013).
2. National Cancer Institute. Common Cancers Type. http://www.cancer.gov/ cancertopics/types/commoncancers (accessed May 20, 2013).
3. Piccart-Gebhart, M. J.; Burzykowski, T.; Buyse, M.; Sledge, G.; Carmichael, J.; Lück, H. J.; Mackey, J. R.; Nabholtz, J. M.; Paridaens, R.; Biganzoli, L.; Jassem, J.; Bontenbal, M.; Bonneterre, J.; Chan, S.; Basaran, G. A.; Therasse, P. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer J. Clin. Oncol. 2008, 26 (12) 1980-1986
4. Fauzee, N. J. S.; Dong, Z.; Wang, Y. L. Taxanes: Promising Anti-Cancer Drugs Asian Pacific J. Cancer Prevent. 2011, 12, 837-851
5. Sparano, J. A.; Wang, M.; Martino, S.; Jones, V.; Perez, E. A.; Saphner, T.; Wolff, A. C.; Sledge, G. W.; Wood, W. C.; Davidson, N. E. Weekly paclitaxel in the adjuvant treatment of breast cancer New Engl. J. Med. 2008, 358, 1663-1671
6. Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations Int. J. Pharm. 2002, 235, 179-192
7. Holmes, F. A.; Walters, R. S.; Theriault, R. L.; Forman, A. D.; Newton, L. K.; Raber, M. N.; Buzdar, A. U.; Frye, D. K.; Hortobagyi, G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer J. Natl. Cancer Inst. 1991, 83, 1797-1805
8. Straubinger, R. M. Biopharmaceutics of paclitaxel (Taxol): formulation, activity and pharmacokinetics. In Taxol: Science and Applications; Suffness, M., Ed.; CRC Press: Boca Raton, FL, 1995; pp 237-258.
9. Couvreur, P.; Tulkens, P.; Roland, M.; Trouet, A.; Speiser, P. Nanocapsules: a new type of lysosomotropic carrier FEBS Lett. 1977, 84 (2) 323-326
10. Couvreur, P.; Kante, B.; Lenaerts, V.; Scailteur, V.; Roland, M.; Speiser, P. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles J. Pharm. Sci. 1980, 69 (2) 199-202
11. Bristol-Myers Squibb. Taxol (paclitaxel) Injection (patientinformation included). http://packageinserts.bms.com/pi/pi-taxol.pdf (accessed May 25, 2013).
12. Merisko-Liversidge, E.; Sarpotdar, P.; Bruno, J.; Hajj, S.; Wei, L.; Peltier, N.; Rake, J.; Shaw, J. M.; Pugh, S.; Polin, L.; Jones, J.; Corbett, T.; Cooper, E.; Liversidge, G. G. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs Pharm. Res. 1996, 13 (2) 272-278
13. Constantinides, P. P.; Lambert, K. J.; Tustian, A. K.; Schneider, B.; Lalji, S.; Ma, W.; Wentzel, B.; Kessler, D.; Worah, D.; Quay, S. C. Formulation development and antitumor activity of a filter sterilizable emulsion of paclitaxel Pharm. Res. 2000, 17 (2) 175-182
14. Weiss, R. B.; Donehower, R. C.; Wiernik, P. H.; Ohnuma, T.; Gralla, R. L.; Trump, D.; Baker, J. R.; VanEcho, D. A.; VonHoff, D. D.; Leyland-Jones, B. Hypersensitivity reactions from taxol J. Clin. Oncol. 1990, 8, 1263-1268
15. Surapaneni, M. S.; Das, S. K.; Das, N. G. Designing paclitaxel drug delivery systems aimed at improved patient outcomes: Current status and challenges ISRN Pharmacol. 2012, 623139
16. Sohn, J. S.; Jin, J. I.; Hess, M.; Jo, B. W. Polymer prodrug approaches applied to paclitaxel Polym. Chem. 2010, 1, 778-792
17. Sigma-Aldrich. Solubility Properties ofPAMAM Dendrimers. http://www.sigmaaldrich.com/materials-science/nanomaterials/dendrimers/ solubility.html (accessed May 28, 2013).
18. Rolland, O.; Turrin, C. O.; Caminade, A. M.; Majoral, J. P. Dendrimers and nanomedicine: multivalency in action New J. Chem. 2009, 33, 1809-1824
19. Nanjwade, B. K.; Bechra, H. M.; Derkar, G. K.; Manvi, F. V.; Nanjwade, V. K. Dendrimers: Emerging polymers for drug-delivery systems Eur. J. Pharm. Sci. 2009, 38, 185-196
20. Tomalia, D. A.; Christensen, J. B.; Boas, U. (2012) The Dendridic State. In Dendrimers, Dendrons, and Dendridic Polymers: Discovery, Applications and Future; Cambridge University Press, Cambridge, UK, 2012; pp 92-95.
21. Teow, H. M.; Zhou, Z.; Najlah, M.; Yusof, S. R.; Abbott, N. J.; D'Emanuelea, A. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier Int. J. Pharm. 2013, 441, 701-711
22. Wang, T. H.; Wang, H. S.; Soong, Y. K. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together Cancer 2000, 88 (11) 2619-2628
23. Luo, Y.; Ziebell, M. R.; Prestwich, G. D. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells Biomacromolecules 2000, 1 (2) 208-218
24. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, V. Cremophor EL the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer. 2001, 37, 1590-1598
25. Gao, Z.; Lukyanov, A. N.; Singhal, A.; Torchilin, V. P. Diacyllipid-polymer micelles as nanocarriers for poorly soluble anticancer drugs Nano Lett. 2002, 2 (9) 979-982
26. Liu, C.; Strobl, J. S.; Bane, S.; Schilling, J. K.; McCracken, M.; Chatterjee, S. K.; Rahim-Bata, R.; Kingston, D. G. I. Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer J. Nat. Prod. 2004, 67 (2) 152-159
27. Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sohma, Y.; Kimura, T.; Kiso, Y. A. Novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: Design and synthesis of isotaxel J. Med. Chem. 2003, 46 (18) 3782-3784
28. Elliott, E.; Sloane, B. F. The cysteine protease cathepsin B in cancer Perspect. Drug Discovery Des. 1996, 6, 12-32
29. Mohamed, M. M.; Sloane, B. F. Cysteine cathepsins: multifunctional enzymes in cancer Nat. Rev. Cancer. 2006, 6, 764-775
30. Nouh, M. A.; Mohamed, M. M.; El-Shinawi, M.; Shaalan, M. A.; Cavallo-Medved, D.; Khaled, H. M.; Sloane, B. F. Cathepsin B a potential prognostic marker for inflammatory breast cancer J. Transl. Med. 2011, 9, 1
31. Bremer, C.; Tung, C. H.; Bogdanov, A.; Weissleder, R. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes Radiology 2002, 222 (3) 814-818
32. Dubowchik, G. M.; Firestone, R. A.; Padilla, L.; Willner, D.; Hofstead, S. J.; Mosure, K.; Knipe, J. O.; Lasch, S. J.; Trail, P. A. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity Bioconjugate Chem. 2002, 13, 855-869
33. Malugin, A.; Kopeckova, P.; Kopecek, J. Liberation of doxorubicin from hpma copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells J. Controlled Release 2007, 124, 6-10
34. Kurtoglu, Y. E.; Mishra, M. K.; Kannan, S.; Kannan, R. M. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers Int. J. Pharm. 2010, 384, 189-194
35. Borgman, M. P.; Ray, A.; Kolhatkar, R. B.; Sausville, E. A.; Burger, A. M.; Ghandehari, H. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy Pharm. Res. 2009, 26 (6) 1407-1418
36. Duncan, R. The dawning era of polymer therapeutics Nat. Rev. Drug Discovery 2003, 2, 347-360
37. Kopecek, J.; Kopeckova, P.; Minko, T.; Lu, Z. R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action Eur. J. Pharm. Biopharm. 2000, 50, 61-81
38. Majoros, I. J.; Myc, A.; Thomas, T.; Mehta, C. B.; Baker, J. R. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality Biomacromolecules 2006, 7 (2) 572-9
39. Deutsch, H. M.; Glinski, J. A.; Hernandez, M.; Haugwitz, R. D.; Narayanan, V. L.; Suffness, M.; Zalkow, L. H. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity J. Med. Chem. 1989, 32 (4) 788-792
40. Ryppa, C.; Mann-Steinberg, H.; Biniossek, M. L.; Satchi-Fainaro, R.; Kratz, F. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin ανβ3 Int. J. Pharm. 2009, 368, 89-97
41. Yang, N.; Ye, Z.; Li, F.; Mahato, R. I. HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells Bioconjugate Chem. 2009, 20 (2) 213-221
42. Zhou, Y.; Yang, J.; Kopeček, J. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells Biomaterials 2012, 33 (6) 1863-72
43. Vadlamudi, R. K.; Wang, R. A.; Mazumdar, A.; Kim, Y. S.; Shin, J.; Sahin, A.; Kumar, R. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor a J. Biol. Chem. 2001, 276, 38272-38279
44. Khandare, J.; Minko, T. Polymer-drug conjugates: Progress in polymeric prodrugs Prog. Polym. Sci. 2006, 31, 359-397
45. Vaidya, A. A.; Lele, B. S.; Kulkarni, M. G.; Mashelkar, R. A. Enhancing ligand-protein binding in affinity thermoprecipitation: elucidation of spacer effects Biotechnol. Bioeng. 1999, 64, 418-25
46. Kingston, D. G. I. Taxol: the chemistry and structure-activity relationships of a novel anticancer agent Trends Biotechnol. 1994, 12, 222-227
47. Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel prodrugs: Toward smarter delivery of anticancer agents J. Med. Chem. 2006, 49 (25) 7253-7269
48. Mortier, K. A.; Zhang, G.-F.; Van Peteghem, C. H.; Lambert, W. E. Adduct formation in quantitative bioanalysis: Effect of ionization conditions on paclitaxel J. Am. Soc. Mass Spectrom. 2004, 15, 585-592
49. Hou, L.; Yao, J.; Zhou, J. Simultaneous LC-MS analysis of paclitaxel and retinoic acid in plasma and tissues from tumor-bearing mice Chromatographia 2011, 73, 471-480
50. Erhan, Y.; Özdemir, N.; Zekioglu, O.; Nart, D.; Ciris, M. Breast carcinomas with choriocarcinomatous features: Case reports and review of the literature Breast J. 2002, 8 (4) 244-248
51. Filho, O. G.; Miiji, L. N. O.; Vainchenker, M.; Gordan, Â. N. Breast cancer with choriocarcinomatous and neuroendocrine features Sao Paulo Med. J. 2001, 119 (4) 154-155
52. L'Azou, B.; Jorly, J.; On, D.; Sellier, E.; Moisan, F.; Fleury-Feith, J.; Cambar, J.; Brochard, P.; Ohayon-Courtès, C. In vitro effects of nanoparticles on renal cells Part. Fibre Toxicol. 2008, 5, 22
53. Kaczirek, K.; Schindl, M.; Weinhäusel, A.; Scheuba, C.; Passler, C.; Prager, G.; Raderer, M.; Hamilton, G.; Mittlböck, M.; Siegl, V.; Pfragner, R.; Niederle, B. Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines J. Clin. Endocrinol. Metab. 2004, 89 (5) 2397-2401
54. Awasthi, N.; Zhang, C.; Schwarz, A. M.; Hinz, S.; Wang, C.; Williams, N. S.; Schwarz, M. A.; Schwarz, R. E. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer Carcinogenesis 2013, 34 (10) 2361-2369
55. GraphPad. http://www.graphpad.com/support/faqid/1566/ (accessed June 2013).
56. Keenan, J.; Liang, Y.; Clynes, M. Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants Anticancer Res. 2004, 24, 433-440
57. Ashikaga, T.; Yoshida, Y.; Hirota, M.; Yoneyama, K.; Itagaki, H.; Sakaguchi, H.; Miyazawa, M.; Ito, Y.; Suzuki, H.; Toyoda, H. Development of an in vitro skin sensitization test using human cell lines: The human cell line activation Test (h-CLAT) I. Optimization of the h-CLAT protocol Toxicol. In Vitro 2006, 20, 767-773
58. Zhang, X.; Stecklein, S.; Behbod, F.; Cohen, M. S. A New Mechanism Of Action For Withaferin A In Breast Cancer: Induction Of Proteasomal-degradation of Notch1 and Notch3 Proteins; 7th Annual Academic Surgical Congress, 2012; Control # ASC20120846.
59. Gondi, C. S.; Rao, J. S. Cathepsin B as a cancer target Expert Opin. Ther. Targets 2013, 17 (3) 281-91
60. Kominami, E.; Tsukahara, T.; Bando, Y.; Katunuma, N. Distribution of cathepsins B and H in rat tissues and peripheral blood cells J. Biochem. 1985, 98 (1) 87-93
61. Cline, E. N.; Li, M. H.; Choi, S. K.; Herbstman, J. F.; Kaul, N.; Meyhöfer, E.; Skiniotis, G.; Baker, J. R.; Larson, R. G.; Walter, N. G. Paclitaxel-conjugated PAMAM dendrimers adversely affect microtubule structure through two independent modes of action Biomacromolecules 2013, 14 (3) 654-64
62. Lacroix, M.; Leclercq, G. Relevance of breast cancer cell lines as models for breast tumours: an update Breast Cancer Res. Treat. 2004, 83 (3) 249-89
63. Nakayama, S.; Torikoshi, Y.; Takahashi, T.; Yoshida, T.; Sudo, T.; Matsushima, T.; Kawasaki, Y.; Katayama, A.; Gohda, K.; Hortobagyi, G. N.; Noguchi, S.; Sakai, T.; Ishihara, H.; Ueno, N. T. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells Breast Cancer Res. 2009, 11, R12
64. Lee, J.; Lilly, G. D.; Doty, R. C.; Podsiadlo, P.; Kotov, N. A. In vitro toxicity testing of nanoparticles in 3D cell culture Small 2009, 5 (10) 1213-21
65. Sayes, C. M.; Reed, K. L.; Warheit, D. B. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles Toxicol. Sci. 2007, 97 (1) 163-80